Latest Mergers And Acquisitions News

Race Oncology has advanced its Phase 1 clinical trial for RC220, submitting ethics approvals and bolstering its cash reserves to $18.78 million following a $5.25 million R&D tax incentive.

ABx Group reports significant progress in its rare earths and bauxite ventures, including enhanced geological models and pilot plant developments supported by key partnerships and government backing.

Axel REE Limited reports a breakthrough in its Brazilian exploration with record high-grade rare earth and gallium assays at the Caladão Project, expanding the mineralised area significantly and securing funding to advance resource definition.

Native Mineral Resources has secured key Queensland gold assets and is advancing refurbishment of the Blackjack Processing Plant, targeting production restart by Q3 2025. The company’s recent capital raises underpin its ambitious development plans.

Nimy Resources advances its Mons Project with significant high-grade copper and gallium mineralisation confirmed at Masson and Block 3 East prospects, supported by a successful capital raise and a CSIRO research grant.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

Askari Metals reports significant exploration advances across its Australian gold and copper projects and secures a new uranium project in Tanzania, supported by fresh funding and leadership updates.

Lefroy Exploration Limited reported a modest net cash decrease in the December quarter, ending with $3.24 million in cash reserves and nearly four quarters of funding available. The company continues to invest heavily in exploration activities despite operating cash outflows.

Gratifii reports a remarkable 110% increase in 2Q FY25 cash receipts, driven by strategic acquisitions and strong client engagement, setting the stage for sustained growth and profitability in the coming quarters.

Novatti Group Limited reports a robust December quarter with a 30% year-on-year revenue increase and a significant reduction in expenses, positioning the fintech on track for positive operating cashflow by mid-2025.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Stonehorse Energy Limited outperformed production forecasts in Q4 2024 despite a revenue dip caused by weak natural gas prices, while advancing new project negotiations in Canada and the US.